Lynk Pharmaceuticals

About Lynk Pharmaceuticals

Lynk Pharmaceuticals is a clinical-stage innovative drug company focused on autoimmune and inflammatory diseases, committed to addressing unmet clinical needs through first-in-class innovation, developing differentiated small-molecule therapies, and providing superior oral alternatives to biologics. The company was founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and expanding to TYK2 signaling pathways, and mastering targeted protein degradation. The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated R&D platform spanning target discovery, molecular design, translational research, and clinical development to advance differentiated therapies for patients worldwide. To date, Lynk Pharmaceuticals has successfully developed and progressed multiple innovative Class 1 new drug candidates and advanced multiple pipeline programs through internal research and development as well as global partnerships.